Literature DB >> 12084295

Dendritic cell-based immunotherapy of renal cell carcinoma.

B J Gitlitz1, R A Figlin, A J Pantuck, A S Belldegrun.   

Abstract

Although mostly resistant to cytotoxic therapy, renal cell carcinoma has been a testing ground for immunotherapy. The approval of interleukin-2 for the treatment of renal cell carcinoma was a landmark "proof of principle" which showed that agents working solely via the immune system can cause durable cancer remission. Dendritic cells are central to immune-mediated surveillance and destruction of abnormal cells. They possess all the components required to educate immune effector cells that can then mediate tumor destruction. In vitro strategies to expand and load dendritic cells with antigens have now led to human vaccine trials in renal cell carcinoma and other malignancies.

Entities:  

Mesh：

Year:  2001        PMID： 12084295     DOI： 10.1007/s11934-001-0025-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  36 in total

Review 1.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.

Authors:  J W Simons; E M Jaffee; C E Weber; H I Levitsky; W G Nelson; M A Carducci; A J Lazenby; L K Cohen; C C Finn; S M Clift; K M Hauda; L A Beck; K M Leiferman; A H Owens; S Piantadosi; G Dranoff; R C Mulligan; D M Pardoll; F F Marshall
Journal:  Cancer Res       Date:  1997-04-15       Impact factor: 12.701

3.  Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.

Authors:  M G Steffens; O C Boerman; J C Oosterwijk-Wakka; G O Oosterhof; J A Witjes; E B Koenders; W J Oyen; W C Buijs; F M Debruyne; F H Corstens; E Oosterwijk
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

4.  The interleukin-2 T-cell system: a new cell growth model.

Authors:  D A Cantrell; K A Smith
Journal:  Science       Date:  1984-06-22       Impact factor: 47.728

5.  Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.

Authors:  R L Paquette; N C Hsu; S M Kiertscher; A N Park; L Tran; M D Roth; J A Glaspy
Journal:  J Leukoc Biol       Date:  1998-09       Impact factor: 4.962

6.  Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

Authors:  R A Figlin; J A Thompson; R M Bukowski; N J Vogelzang; A C Novick; P Lange; G D Steinberg; A S Belldegrun
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

7.  High-dose aldesleukin in renal cell carcinoma: long-term survival update.

Authors:  R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; G Fyfe
Journal:  Cancer J Sci Am       Date:  1997-12

8.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Authors:  S A Rosenberg; M T Lotze; J C Yang; S L Topalian; A E Chang; D J Schwartzentruber; P Aebersold; S Leitman; W M Linehan; C A Seipp
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

9.  Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.

Authors:  M A Cheever; P D Greenberg; C Irle; J A Thompson; D L Urdal; D Y Mochizuki; C S Henney; S Gillis
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307
View more
  1 in total

Review 1.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.